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Infections post transplant
Changing pattern of bacterial susceptibility to antibiotics in
hematopoietic stem cell transplant recipients
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Summary:
Adequate infection prophylaxis and empirical antibiotic
therapy are of critical importance after hematopoietic
stem cell transplantation (HSCT). We examined the
evolution of bacterial susceptibility to antibiotics in 492
patients (198 allografts and 294 autografts) transplanted
between 1982 and 1999 and evaluated whether cipro-
floxacin prophylaxis and an empirical antibiotic regi-
men (glycopeptide + third-generation cephalosporin)
were still valid. We collected all susceptibility tests per-
formed during the initial hospitalization on blood cul-
tures as well as routine surveillance cultures and ana-
lyzed susceptibility to ciprofloxacin and to major
antibiotics used in our unit. Gram-positive cocci rapidly
became resistant to ciprofloxacin (susceptibility around
70% in 1990 to less than 20% in 1998) but sensitivity
to glycopeptides remained unaltered. There was a rapid
decline in the number of patients colonized with Gram-
negative bacilli in the early years of ciprofloxacin
prophylaxis. However, susceptibility to ciprofloxacin fell
sharply from around 90% in 1990 to around 30% in
1999. In parallel, susceptibility to ceftazidime also
decreased to less than 80% in recent years. Piperacillin
( tazobactam) did not show any variation over time
and its efficacy remained too low (about 60%). Imip-
enem as well as recently introduced cefepim and merop-
enem showed stable and excellent profiles (90%
susceptibility). In conclusion: (1) quinolone prophylaxis
has now lost most of its value; (2) the choice of a third-
generation cephalosporin for empirical antibiotic ther-
apy may no longer be the best because of the emergence
of Gram-negative strains resistant to -lactamases, such
as Enterobacter sp. More appropriate regimens of
empirical antibiotic therapy in HSCT recipients may be
based on the use of a carbapenem or fourth-gener-
ation cephalosporin.
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Infections are still one of the major sources of compli-
cations after hematopoietic stem cell transplantation
(HSCT). About 50 to 60% of febrile episodes are thought
to be related to an infectious process and one-third of these
are caused by bacterial infection.1,2 Major sites of infection
include the gastrointestinal tract, respiratory tract and skin.2
To lower this risk of infection, a number of measures are
taken, including the use of antibiotics such as quinolones.
However, the value of quinolone prophylaxis has been
questioned in recent years.2–6 In addition, it has become
standard practice to use empiric antibiotic therapy when-
ever a bacterial infection is suspected. However, there has
always been a lot of controversy about the most appropriate
antibiotic regimen to use in this setting.2,7–11 On the basis
that on the one hand the most frequent bacterial infectious
episodes are due to Gram-positive bacteria, but that on the
other hand the most severe ones are caused by Gram-nega-
tive organisms, since 1991 we elected to use a combination
of a glycopeptide (vancomycin) and a third-generation
cephalosporin (ceftazidime).
In 2000, we conducted an evaluation of our policy of
prophylactic and empiric antibiotic therapy. For this pur-
pose, we collected all susceptibility tests performed on all
surveillance and diagnostic bacterial cultures in 492 con-
secutive recipients of an HSC transplant between 1982 and
1999. We classified the most frequent bacteria encountered
into five categories and examined the evolution over time
of their sensitivity to the quinolone (ciprofloxacin) used as
prophylaxis and to the i.v. antibiotics most frequently used
in our department. This analysis resulted in major changes
in our policy, including abandoning quinolone prophylaxis
and changing our choice of empiric antibiotic therapy.
Patients and methods
We collected data from 492 consecutive recipients of an
HSC transplant performed between 1982 and 1999 in our
department. The 17 years of follow-up were divided into
eight consecutive periods, each including about 60 patients:
period 1 (1982 to September 1987: old hospital), period 2
(October 1987 (new hospital) to 1990), period 3 (1991 to
1992), period 4 (1993 to 1994), period 5 (1995 to 1996),
period 6 (1997), period 7 (1998) and period 8 (1999). Cip-
rofloxacin prophylaxis (500 mg twice daily orally) was
introduced in period 3. The empiric antibiotherapy regi-
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mens used were amikacin + piperacillin (1982–1990) and
ceftazidime + vancomycin (1991–1999). Imipenem has
been used as the second-line empiric regimen. Median age
at time of transplant was 37 years, ranging from 10 months
to 66 years. There were 198 allografts (40% of cases) and
294 autografts (60% of cases). There were 235 females
(48%) and 257 males (52%). For allotransplants, the source
of stem cells was bone marrow (n = 154), peripheral blood
(n = 40) or cord blood (n = 4). Autotransplants were done
with PBSC (n = 217), bone marrow (n = 45) or both
(n = 32). The population described consisted of patients
suffering from non-neoplastic disorders (n = 17), AML
(n = 107), NHL (n = 75), multiple myeloma (n = 63), ALL
(n = 56), CML (n = 47), myelodysplastic syndromes
(n = 17), Hodgkin’s disease (n = 16), breast cancer (n = 66)
or other solid tumours (n = 28). Eighty-seven patients
(18%) died during their initial hospitalization. Overall, 54%
of patients are alive and 46% died. Over 50% of them died
of their original disease and 11% of infection.
We collected all susceptibility tests performed on all sur-
veillance and diagnostic bacterial cultures performed during
the whole initial hospitalization. Routine surveillance cul-
tures were carried out twice a week on a set of samples
obtained from various body sites (nose, throat, tongue, spu-
tum, skin, penis, vagina, stools, anus and urine). In some
cases, it is possible that bacteria present at different sites
or at different time points actually represented the same
strain. In cases of simultaneous occurrence at various sites,
the laboratory generally provided only one susceptibility
test, but it is possible that the same strain was occasionally
counted twice when detected at two different time points
after transplantation. Finally, to better separate colonizing
from invasive microorganisms, we carried out a separate
analysis of susceptibility to all bacteremias.
Bacteria were classified into four categories, taking into
account both their relative frequency and their biological
characteristics. These four categories were Coagulase-nega-
tive Staphylococci, Enterococci, Streptococci and Gram-
negative bacilli. We could not consider Staphylococcus
aureus because only 14 isolates were found throughout the
study period. For Enterococci and Streptococci, data were
collected on six antibiotics: ampicillin, vancomycin, teico-
planin, imipenem, amikacin and ciprofloxacin. For coagul-
ase-negative Staphylococci, the same antibiotics were
evaluated, except that ampicillin was replaced by oxacillin.
For Gram-negative bacilli, we compared piperacillin (alone
or in association with Tazobactam), ceftazidime, cefepim,
Table 1 Enterococci
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Ampicillin 340 92 77 94 16 94 61 97 102 86 20 90 9 100 35 100 20 90
Vancomycin 333 99.6 72 100 22 100 59 98 95 100 23 100 8 100 35 100 19 100
Teicoplanin 96 100 0 0 20 100 10 100 8 100 3 100 35 100 20 100
Imipenem 15 100 14 100 0 0 1 100 0 0 0 0
Amikacin 143 47 71 49 15 27 26 46 6 100 2 100 4 50 16 25 3 67
Ciprofloxacin 185 46 0 6 67 59 56 56 38 13 46 5 20 36 19 20 65
imipenem, meropenem, aztreonam, amikacin and cipro-
floxacin. The antibiotics analyzed were the ones most fre-
quently used in our department for empiric or specific ther-
apy, plus ciprofloxacin which was used prophylactically.
Identification and antimicrobial susceptibility testing were
performed according to the manufacturer’s recommen-
dations by using the SCEPTOR system (BD, Brussels,
Belgium) in 1982–1992 or the automated VITEK system
since 1993 (BioMerieux, St Louis, MO, USA). MICs were
determined and interpretation category results (susceptible,
intermediate and resistant) were also routinely provided.
Interpretation criteria were based on updated NCCLS
(National Committee for Clinical Laboratory Standards)
breakpoints. Classification into sensitive and resistant
strains was done on the basis of MIC.
Results
Enterococci (Table 1)
Table 1 describes the evolution of the sensitivity of enteroc-
occi to the six selected antibiotics. Vancomycin and teico-
planin retain a nearly 100% efficacy throughout the periods
(only one strain resistant to vancomycin in period 3). Sensi-
tivity to ampicillin is a little lower (P  0.0001) but
remains stable at over 90%. The number of strains tested
for imipenem or amikacin in the latest periods is too small
to draw any firm conclusion. Sensitivity to ciprofloxacin is
lower (P  0.0001) and has substantially declined
(P = 0.0091) from periods 2–3 (57%) to periods 4–5 (39%)
to periods 6–7 (20%), although it is more favourable in the
last period.
There were only seven Enterococci bacteremias. Suscep-
tibility to vancomycin, teicoplanin and ampicillin was
100% while that to ciprofloxacin (33%) and amikacin
(20%) were lower.
Streptococci (Table 2)
The small number of strains tested does not allow adequate
data interpretation. The available evidence indicates no
particular trend over time, with an excellent sensitivity to
vancomycin and ampicillin but significantly lower sensi-
tivity to amikacin (P  0.0001) or ciprofloxacin
(P  0.0001).
There were 22 bacteremias due to Streptococci. Sensi-
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Table 2 Streptococci
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Ampicillin 58 95 7 100 16 88 10 90 6 100 5 100 4 100 5 80 5 100
Vancomycin 70 96 13 77 18 100 13 100 6 100 6 100 4 100 5 100 5 100
Teicoplanin 0 0 0 0 0 0 0 0 0
Imipenem 3 100 2 100 1 100 0 0 0 0 0 0
Amikacin 53 58 12 83 17 47 7 29 3 100 2 50 3 67 5 60 4 50
Ciprofloxacin 37 51 0 7 57 10 50 5 60 4 75 3 0 4 50 4 50
Table 3 Coagulase-negative Staphylococci
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Oxacillin 1273 26 394 34 226 27 218 8 251 15 56 5 51 10 54 24 23 13
Vancomycin 1243 99.5 358 99.7 236 100 220 99.5 241 100 61 97 50 100 54 100 23 100
Teicoplanin 185 99 0 1 100 56 100 23 91 21 100 12 100 49 100 23 100
Imipenem 103 80 76 82 25 72 0 0 1 100 0 1 100 0
Amikacin 659 63 418 69 0 160 60 0 0 5 100 0 53 36 23 30
Ciprofloxacin 762 20 0 110 52 229 14 243 13 62 8 51 8 54 31 23 17
tivity to vancomycin (100%) and ampicillin (89%, NS)
were excellent, but this was low to amikacin (40%,
P 0.0001) and ciprofloxacin (28%, P 0.0001). There
was no change over time.
Coagulase-negative Staphylococci (Tables 3 and 4)
Vancomycin and teicoplanin always maintained excellent
results and, as for Enterococci, resistance to glycopeptides
remained extremely rare (Table 3). Soon after its introduc-
tion, there was a very rapid and major loss of sensitivity
to ciprofloxacin in periods 3–6 (14% compared to 52% in
period 2, P 0.0001), although some recovery was
observed in periods 7–8 (27%, P = 0.0005 compared to per-
iods 3–6). Oxacillin is now ineffective in over 80% of cases
(P  0.0001) and sensitivity to amikacin has also declined
seriously from periods 1–2 to periods 7–8 (P  0.0001).
There were 116 bacteremias caused by coagulase-nega-
Table 4 Bacteremias with coagulase-negative Staphylococci
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Oxacillin 116 40 14 57 16 62 23 43 11 36 23 26 9 33 15 33 5 0
Vancomycin 115 100 13 100 16 100 23 100 11 100 23 100 9 100 15 100 5 100
Teicoplanin 24 100 0 0 2 100 2 100 1 100 1 100 13 100 5 100
Imipenem 11 100 0 9 100 0 0 0 0 2 100 0
Amikacin 38 58 14 64 14 86 0 0 0 0 6 50 4 0
Ciprofloxacin 97 47 0 11 100 23 43 11 36 23 48 9 11 15 60 5 0
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tive staphylococci (Table 4). Susceptibility results parallel
those observed with all strains (Table 3) for vancomycin
(NS), teicoplanin (NS) and amikacin (NS), but sensitivities
to ciprofloxacin (P  0.0001) and oxacillin (P = 0.0015)
are a little superior for bacteria isolated from blood
cultures.
Gram-negative bacilli (Tables 5 and 6)
After a sustained decrease in the incidence of Gram-nega-
tive bacteria through period 5, the number of strains has
increased again in recent years (Table 5). In particular,
Pseudomonas strains have become very rare. The results of
period 1 should be interpreted with caution because at that
time cefotaxime was sometimes tested instead of ceftazid-
ime. Susceptibility to ciprofloxacin has fallen from 93%
when it was introduced, to 32% in 1999 (P  0.0001). Cef-
tazidime has also lost some of its efficacy, decreasing from
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Table 5 Gram-negative bacilli
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Piperacillin 781 60 303 50a 189 79 53 70 121 55 26 65 45 60 14 71 30 37
Tazobactam 153 75 0 0 0 0 0 12 100 73 73 68 74
Ceftazidime 823 84 245 76a 169 97 52 89 99 90 21 100 69 78 95 79 73 71
Imipenem 508 94 106 94 77 94 6 100 82 89 20 90 58 95 89 100 70 91
Aztreonam 463 81 1 100 76 88 44 84 116 85 21 86 48 69 86 78 71 79
Amikacin 920 93 307 91 171 95 53 98 128 95 22 100 71 89 94 97 74 84
Ciprofloxacin 533 58 0 95 93 51 65 127 47 27 59 69 61 89 48 71 32
Cefepim 148 94 0 0 0 0 0 13 100 70 99 65 88
Meropenem 129 95 0 0 0 0 0 3 100 66 100 60 90
aTesting was often done for cefotaxime instead of ceftazidime and ticarcillin instead of piperacillin.
94% in periods 2–5 to 76% thereafter (P  0.0001). Further
comparison of periods 2–5 vs periods 6–8 demonstrates
moderate but significant reductions in the sensitivity of
Gram-negative bacilli to piperacillin (69% vs 54%,
P = 0.0053), aztreonam (86% vs 76%, P = 0.0064) and ami-
kacin (96% vs 90%, P = 0.0064), but stable values for imi-
penem (91% vs 96%, NS). This emergence of resistant
strains is partly related to Enterobacter species but also to
a few Pseudomonas strains in the last period. Finally,
cefepim and meropenem maintain their efficacy to 90%
since their introduction. We also examined the suscepti-
bility to a combination of ceftazidime + amikacin. Among
316 doubly tested strains, 96% were sensitive to either anti-
biotic, but this has tended to decrease in recent years (99%
for periods 2–5 versus 90% for periods 6–8 (80% in period
8), P = 0.0002). For the combination of amikacin +
cefepim, the figure for periods 6–8 was 96% (NS). The
susceptibility of Gram-negative bacilli now remains excel-
lent for imipenem, meropenem or cefepim, while ceftazid-
ime, aztreonam and piperacillin with or without tazobactam
are entirely insufficient.
There were 52 bacteremic episodes with Gram-negative
bacilli (Table 6). These isolates tended to be less suscep-
tible to ceftazidime (61% vs 84%, P  0.0001), aztreonam
(61% vs 81%, P = 0.0094) and imipenem (83% vs 94%,
P = 0.0202), but more sensitive to ciprofloxacin (85% vs
Table 6 Bacteremias with Gram-negative Bacilli
All Period 1 Period 2 Period 3 Period 4 Period 5 Period 6 Period 7 Period 8
n % n % n % n % n % n % n % n % n %
tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive tested sensitive
Piperacillin 46 63 12 8a 5 80 4 100 3 100 9 78 9 89 0 4 50
Tazobactam 7 71 0 0 0 0 0 0 3 100 4 50
Ceftazidime 52 61 12 8a 6 66 4 100 5 100 9 67 9 100 3 100 4 25
Imipenem 30 83 4 75 1 100 3 67 1 100 5 80 9 100 3 100 4 75
Aztreonam 28 61 0 3 66 2 100 4 25 5 80 7 86 3 33 4 25
Amikacin 50 86 12 83 5 100 4 75 5 80 8 88 9 100 3 100 4 50
Ciprofloxacin 33 85 0 0 4 100 5 100 8 75 9 100 3 100 4 25
Cefepim 5 80 0 0 0 0 0 0 3 100 2 50
Meropenem 6 83 0 0 0 0 0 0 3 100 3 67
aTesting was often done for cefotaxime instead of ceftazidime and ticarcillin instead of piperacillin.
58%, P = 0.0023) than those found in surveillance cultures.
Figures were comparable for piperacillin and amikacin, but
the numbers were too low to allow interpreting meropenem,
cefepim and tazobactam sensitivities.
Discussion
We conducted a retrospective survey on the evolution of
bacteria sensitivity to major antibiotics used as prophylaxis
or empiric therapy in recipients of a hematopoietic stem
cell transplant in our transplantation unit between 1982 and
1999. Several interesting results emerged. Since the intro-
duction of quinolone prophylaxis, there has been a rapid
emergence of resistant strains of Gram-positive as well as
Gram-negative bacteria. On the other hand, whereas we did
not encounter Gram-positive bacteria that were resistant to
glycopeptides, a significant proportion of Gram-negative
bacteria became resistant to the third-generation cephalo-
sporin used in our empirical antibiotic schedule, although
some of these resistant strains would be sensitive to the
addition of amikacin. These results were rather similar
among strains isolated from surveillance cultures or from
blood cultures obtained during bacteremias. These obser-
vations should bring about major changes in our prophylac-
tic and therapeutic policy.
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fallen dramatically in the years following its systematic use
as prophylaxis in our unit. This is in keeping with the find-
ings of previous studies.3–6 Likewise, Gram-negative bac-
teria, including Pseudomonas as well as Enterobacteriacae,
have also developed a high degree of resistance to quino-
lones. These observations should make us abandon the use
of quinolone prophylaxis. Indeed, although quinolone
prophylaxis has been shown in the past to efficiently reduce
the incidence of Gram-negative bacteremia, it has allowed
the development of resistance and has never been associa-
ted with a reduction in infection-related mortality.2–6 How-
ever, the problem of resistance not only stems from quino-
lone use in transplant patients but from their more
widespread use in these patients during induction or salvage
chemotherapy before stem cell transplantation. Therefore,
it cannot be excluded that a more targeted use of quinolone
prophylaxis in transplant recipients only could regain some
interest in the future.
The frequency and severity of infections is inversely
related to neutrophil counts and duration of aplasia. Fur-
thermore, bacteriological identification tests are not fast,
sensitive and/or specific enough, although molecular
biology techniques may improve this situation in the
future.2 Many infections cannot be documented sufficiently
early or even at all, and therefore early use of empirical
antibiotic therapy is necessary in severely neutropenic
patients. An empirical schedule should be chosen on the
basis of cost, potential side-effects, development of resist-
ance and pattern of infections in a particular type of
patient.1 In 1997, the Infectious Diseases Society of Amer-
ica established international guidelines for first-line anti-
biotic therapy in neutropenic patients with fever of undeter-
mined origin.2 There were three possible schedules: (1)
ceftazidime + vancomycin (if a glycopeptide is necessary);
(2) monotherapy with ceftazidime or imipenem (or with
cefepim or meropenem); (3) anti-Pseudomonas -
lactam + aminoglycoside. The value of the third schedule
is debatable. First, while one of its advantages was sup-
posed to be its faster bactericidal action, monotherapy with
a carbapenem resulted in responses that occurred with the
same delay.7 Second, although the association of a -lactam
and an aminoglycoside was thought to be synergistic,
response rates of this classical schedule or a monotherapy
were shown to be identical.7 Finally, whereas a previous
study indicated that this association could lower the risk of
resistance,8 another report showed that the addition of an
aminoglycoside to imipenem did not prevent the emergence
of imipenem-resistant Pseudomonas.12
The emergence of multiresistant Gram-negative bacteria
in our patient population is in part related to the occurrence
of Enterobacter sp. in recent years. Infection by a multi-
resistant Enterobacter is correlated in 69% of cases with
previous administration of a -lactam and above all a third-
generation cephalosporin.13–18 Therefore, based on our epi-
demiology and on literature data showing that monotherap-
ies seem to be as efficient and well tolerated as classical
associations,7 it is clear that we have to change our empiri-
cal antibiotic therapy regimen and replace ceftazidime with
either a fourth-generation cephalosporin or a carbapenem.
On the other hand, our in vitro data for Gram-negative
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bacilli would suggest that the addition of amikacin to cefta-
zidime would enhance the efficacy of this empiric regimen.
However, as susceptibility to this association has decreased
in recent years, the combination of cefepim and amikacin
would appear to be preferable in our patient population.
In addition, the use of a glycopeptide in a first-line
empirical regimen should be abandoned. The current litera-
ture is unanimous on that point.13,19–23 Although the number
of Gram-positive bacteremias has increased in neutropenic
patients, vancomycin has never been shown to reduce the
mortality rate when it is used empirically. Even if it is not
(yet) the case in our unit, the emergence of resistant Gram-
positive enterococci in the US7–9 should incite us to limit
the use of vancomycin to cases where bacteriological docu-
mentation or a clinical argument (catheter infection, known
colonization, mucositis) exist. Both vancomycin and teico-
planin remain perfect choices for the treatment of infections
with coagulase-negative staphylococci, enterococci and
streptococci in our unit.
From the results of our retrospective survey, major
changes should be implemented in our unit, including aban-
doning quinolone prophylaxis and modifying our standard
regimen of empiric antibiotic therapy. These changes may
not be adequate for other hospitals because they need to be
based on the local epidemiology. However, it is obvious
that a thoughtful policy of antibiotic therapy should be in
place in every transplant unit because a time relationship
between antibiotic use and resistance has been well estab-
lished and it is in departments which use antibiotics the
most that the prevalence of resistant bacteria is the high-
est.5,7,12–14,16,17,19,24 There is no unique solution for the con-
trol of resistant strains but some steps can be con-
sidered12,13,20,25,26 including constitution of an information
and surveillance team, careful monitoring of the use of key
antibiotics, staff education, and periodic rotation among
systemic antibiotics with different modes of action.
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